SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. PT. A live webcast of the presentation will be accessible on the “Events” page of the BBOT website at https://investors.bbot ...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in November 2025. The employee received non-qualified stock options to purchase 53,060 shares of BBOT common stock, par value $0.0 ...

Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) announced two poster presentations for BBO-10203, a first-in-class oral small molecule targeting RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) scheduled for December 9-12, 2025 [1] Group 1: Product Overview - BBO-10203 is designed to selectively block the interaction between RAS and PI3Kα, inhibiting RAS-driven PI3Kα-AKT signaling in tumors without causing hyperglycemia [4] - The drug is agnostic to the mutational status of RAS or PI3Kα, potentially treating tumors driven by KRAS or PI3Kα mutations, which are the most mutated oncogenes in human cancer [4] Group 2: Clinical Trials - BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, as well as KRAS mutant colorectal or non-small cell lung cancer [4] - The presentations at SABCS include data on the efficacy of BBO-10203 alone and in combination with fulvestrant or ribociclib in breast cancer models [6] Group 3: Company Background - BBOT is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by prevalent oncogenes [5]

Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies and has announced poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [1][2] Company Overview - BBOT is advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors [3] Conference Presentations - The company will present BBO-11818, an orally bioavailable, highly potent and selective non-covalent pan-KRAS inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models during a poster session on October 23 [4] - Another presentation will feature BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, which inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia, scheduled for October 25 [4]

Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies and will participate in two investor conferences in September 2025 [1][5]. Company Overview - BBOT is advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors [4]. Conference Participation Details - BBOT will participate in the Cantor Global Healthcare Conference with a fireside chat scheduled for Thursday, September 4 at 8:35 a.m. ET, along with hosting investor meetings in New York [5]. - The company will also participate in the Morgan Stanley Global Healthcare Conference with a fireside chat on Monday, September 8 at 7:45 a.m. ET, and will host additional investor meetings in New York [5].

Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) has successfully completed its business combination with Helix Acquisition Corp. II, marking a significant milestone for the company as it transitions to a public entity focused on RAS-pathway malignancies [1][3][4] Company Overview - BBOT is a clinical-stage biopharmaceutical company dedicated to developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by these prevalent oncogenes [7] Business Combination Details - The business combination was approved by Helix's shareholders on August 4, 2025, and officially closed on August 11, 2025, with Helix changing its name to BridgeBio Oncology Therapeutics, Inc. [1][2] - The combined entity is expected to have approximately $490 million in cash, cash equivalents, and marketable securities, which includes BBOT's existing cash of about $130 million and net proceeds of approximately $365 million from the business combination [3][4] Investor Support - The business combination had a relatively low redemption rate of approximately 39%, indicating strong investor confidence in BBOT's vision and pipeline [3][4] - The PIPE investment was led by Cormorant Asset Management, with participation from several prominent institutional investors, raising a total of $261 million [4][5] Pipeline and Development Focus - BBOT plans to utilize the net proceeds from the business combination to accelerate the development of its pipeline of RAS-targeted oncology drug candidates, which include BBO-8520, BBO-10203, and BBO-11818, each targeting specific cancer mutations [10][11] - The company is committed to advancing transformative therapies for patients facing deadly cancers mediated by the RAS pathway, with ongoing clinical trials for its drug candidates [3][10]